SCHEMBL6517385

SCHEMBL6517385

CC(C)(C)[Si](C)(C)OCCOc1cccc2[nH]c(C(F)F)nc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.38
DRD4 P21917 2/20 0.38
DRD3 P35462 2/20 0.38
ALDH1A1 P00352 2/20 0.37
POLB P06746 1/20 0.37
GNRHR P30968 4/20 0.36
HTR1A P08908 1/20 0.36
HTR1D P28221 1/20 0.36
HTR1B P28222 1/20 0.36
CBFB Q13951 2/20 0.36
DUT P33316 2/20 0.34
PIK3CB P42338 2/20 0.33
MCHR1 Q99705 4/20 0.33
PDE5A O76074 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
TP53 P04637 1/20 0.32
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2812508 0.83 ALDH1A1 (0.42) DRD2DRD4DRD3ALDH1A1POLB
SCHEMBL3372705 0.81 DRD2 (0.44) DRD2DRD4DRD3ALDH1A1POLB
SCHEMBL6526190 0.79 PDE5A (0.45) DRD2DRD4DRD3ALDH1A1POLB
SCHEMBL909787 0.79 CBFB (0.54) DRD2DRD4DRD3ALDH1A1POLB
SCHEMBL3368794 0.78 DRD2 (0.39) DRD2DRD4DRD3ALDH1A1GNRHR
SCHEMBL13164363 0.78 PDE5A (0.46) DRD2DRD4DRD3ALDH1A1POLB
SCHEMBL12847244 0.77 HTR1B (0.47) DRD2DRD4DRD3ALDH1A1POLB
SCHEMBL477289 0.74 ALDH1A1 (0.50) ALDH1A1POLBCBFBMCHR1PDE5A
SCHEMBL31157033 0.74 ALDH1A1 (0.50) ALDH1A1POLBCBFBMCHR1PDE5A
SCHEMBL13164589 0.73 PIK3CB (0.55) GNRHRHTR1AHTR1DHTR1BPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053907-A1 SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053907-A1 SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY PIK3CA, PIK3R5, PIK3CD DRD2 3438/4885DRD4 4080/4885DRD3 3977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.